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Although angiotensin (Ang)II-induced Janus-activated kinase (JAK)2 phosphorylation was
reported to be enhanced in failing human cardiomyocytes, the downstream balance
between cardio-protective (signal transducer and activator of transcription-STAT3) and the
pro-inflammatory (STAT2 and STAT5) response remains unexplored. Therefore STATs
phosphorylation and putative genes overexpression following JAK2 activation were investigated
in isolated cardiomyocytes obtained from failing human hearts (n = 16), and from
non-failing(NF) hearts of humans (putative donors, n = 6) or adult rats. In NF myocytes
Ang II-induced JAK2 activation was followed by STAT3 phosphorylation (186  45% at
30 min), with no STAT2 or STAT5 response. The associated B cell lymphoma (Bcl)-xL
overexpression (1.05  0.39 fold) was abolished by both JAK2 and extracellular signal-regulated
kinase (ERK)1/2 inhibitors (AG490, 10 mM, and PD98059, 30 mM, respectively), whereas Fas
ligand (Fas-L) response (0.91  0.21 fold) was inhibited only by p38MAPK antagonism
(SB203580, 10 mM). In failing myocytes Ang II-induced JAK2 activation was followed by STAT2
(237  38%) and STAT5 (222  31%) phosphorylation, with no STAT3 response. No changes in
Bcl-xL expression were observed, and the associated Fas-L gene overexpression (1.14  0.27 fold)
being abolished by p38 mitogen-activated protein kinase (MAPK) antagonism. The altered JAK2
induced STATs response in human failing cardiomyocytes may be of relevance for the
progression of cardiac dysfunction in heart failure.
Introduction
Recent evidence shows that the activation of the signal trans-
ducer and activator of transcription (STAT)3 in response to
various pathophysiologic stimuli promotes cardiomyocytes
survival and hypertrophy as well as cardiac angiogenesis,
suggesting that STAT3 is beneficial to the heart.1 In human
heart failure the expression and phosphorylation levels of
STAT3 were reported to be reduced.2 Mice with postnatal
cardiomyocyte-specific disruption of STAT3 develop dilated
cardiomyopathy and heart failure, which leads to premature
death,3,4 so that the possibility that the decreased activation of
STAT3 may contribute to the development of heart failure in
patients was raised.
STAT3 activation is mediated by Janus-activated kinase
(JAK)2 through phosphorylation of receptor tyrosine residues.5,6
In addition to tyrosine phosphorylation STAT3 was also
reported to require extracellular signal-regulated kinase
(ERK)1/2 induced serine phosphorylation to exert full tran-
scriptional activity.7 JAK2 response to Angiotensin (Ang)II
was found to be enhanced in human failing cardiomyocytes,8
where conversely ERK1/2 response to Ang II was reported to
be impaired.9 However, information regarding events down-
stream JAK2 in human failing cardiomyocytes, and in parti-
cular the STATs response to Ang II, is lacking. The signaling
pathway activated by JAK2 may indeed lead to different final
responses depending on the selective phosphorylation of
different elements of the STAT family. Besides the beneficial
effect played by STAT3, other STATs have been reported to
play a role in maladaptive signaling, such as STAT2, which is
being involved in type I interferon signaling,10,11 and STAT5
reported to stimulate angiotensinogen promoter activity in
models of ischemia/reperfusion.12
The present study has therefore been designed to investigate
in Ang II stimulated cardiomyocytes (1) the relationship
between the activation of STAT2, STAT3, or STAT5 and
the expression of interferon regulatory factor-1 (IRF-1),13
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Fas ligand (Fas-L)14 and B-cell lymphoma-xL (Bcl-xL);15 (2)
the crosslink between JAK/STAT and mitogen-activated protein
kinase (MAPK) (ERK1/2 and p38MAPK) in the control of gene
expression; and finally (3) changes in the downstream balance
between cardio-protective STAT3, and the pro-inflammatory
STAT2 and STAT5 pathway in heart failure.
Experimental
Source of tissues
Human hearts were obtained from patients who underwent
cardiac transplantation due to dilated (DCM, n = 8) or
ischemic cardiomyopathy (ICM, n = 8), and from 6 putative
organ donors with no history or signs of heart disease (NF =
non-failing hearts) (Table 1). Subjects with arterial hyper-
tension, or with a recent history of myocardial infarction (less
than 6 months ago), or echocardiographic evidence of valve or
congenital heart disease were not considered for the study.
Diagnosis of ICM or DCM was based on clinical and echo-
cardiographic examination, cardiac catheterization, and coronary
angiography. Myocardial tissue was obtained from a portion of
the left ventricular free wall during cardiac transplantation. The
protocol of this study complies with the principles of the Helsinki
declaration and was approved by our institution. All patients gave
their informed written consent to participate and to have their
hearts used for the study.
Non-failing ventricular myocytes were also obtained from
the hearts of male adult Wistar Hant rats (275 to 300 g body
weight) (Harlan Laboratories, Milan, Italy). Our investigations
conform to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH Publication No. 85–23, revised 1996), and all procedures
were performed in accordance with the animal care guidelines
of Federation of Laboratory Animal Science Associations.
Myocytes isolation
All studies were performed on freshly-isolated ventricular
myocytes. After explantation, human hearts were placed
in cardioplegic solution and immediately transferred to the
laboratory where myocytes were immediately isolated by an
enzymatic digestion method as previously described.8,16
Briefly, to clear the myocardial vasculature of retained blood
cells, a coronary artery branch was cannulated and tissue was
perfused for 10–15 min with a calcium-free basic buffer (Basic
Buffer, BB), composed of Jocklik modified minimal essential
medium (MEM Joklik; Sigma M0518, Sigma Chemical Co.,
St. Louis, Missouri, USA) supplemented with glutamine (Sigma
G5763; 0.3 g L1), taurine (Sigma T0625; 1.25 g L1), HEPES
(Sigma H3375; 2.9 mM), insulin (20 U L1), 5 mL L1
Penicillin-Streptomycin (Sigma P3539; 50 U mL1 and
0.05 mg mL1, respectively), and CaCl2 (7.5 mM), pH 7.4. The
basic buffer has previously been filtered through filters of 0.2 mm
pore size. Perfusion was then switched to collagenase solution,
composed of 0.5 mg mL1 of Worthington type II collagenase
(100 U mL1) in BB supplemented with CaCl2 30 mM
(20 mL min1 for 20–25 min). The collagenase-perfused tissue
was then minced and the tissue collected in tubes containing BB
supplementedwith bovine serum albumin (0.5%), CaCl2 (0.3mM),
and taurine (10 mM). Individual myocytes were then released from
the tissue by mechanical agitation. The suspension was filtered
through sterile gauze to separate cells from tissue mass. The
populations of cells were then washed using two complete cycles
of low-speed centrifugation. The dispersed cells were finally
preplated for 30 min to minimize fibroblast contamination.
Rats were injected intraperitoneally with 0.5 mL heparin
(Epsoclar 5000 U mL1) 30 min prior to killing by decapitation.
Then aorta was cannulated and perfused with a calcium-free
buffer (blood washout) for 10–15 min and then withWorthington
type II collagenase (100 U mL1) for 15 min. The collagenase-
perfused tissue was then minced and shaken in a resuspension
buffer (HEPES-MEM buffer supplemented with bovine serum
albumin 0.5%, 0.3 mM CaCl2, and 10 mM taurine).
Typical preparations contained 60–70% rod-shaped, quies-
cent, calcium-tolerant and trypan blue-excluding myocytes
which had well-defined, regular cross-striations and sarcomere
patterns (Fig. 1). According to their appearance under phase
contrast microscopy and with immunocytochemical staining
(antisarcomeric alpha-actinin and antiskeletal myosin anti-
bodies; both from Sigma Chemical Co.), non-myocyte cells
were found to account for less than 2% of the total cells.8,16
Myocytes stimulation
After isolation, myocytes (105 cell mL1) were suspended in
Dulbecco’s Modified Eagle’ Medium (DMEM) (pH 7.2–7.4)
Table 1 Characteristics of subjects investigated
Clinical
characteristics NF ICM DCM
ANOVA
Po
Age, years 46  7 55  7 55  9 ns
Gender (M/F) 5/1 5/3 6/2 ns
BSA, m2 1.84  0.12 1.90  0.15 1.80  0.07 ns
SAP, mmHg 121.7  14.2 115.7  3.4* 113.8  6.1* 0.05
LVEDDI, mm m2 28.7  2.5 45.1  5.2* 48.7  5.0* 0.05
LVESDI, mm m2 19.0  3.1 31.9  3.6* 36.6  6.4* 0.05
EF (%) 62.7  4.5 28.2  4.3* 21.7  4.5* 0.05
MPAP, mmHg 19.3  1.7 34.7  6.7* 34.8  5.2* 0.05
CI, L m2 min1 2.86  0.13 1.81  0.50* 1.87  0.23* 0.05
NF, non-failing; ICM, ischemic cardiomyopathy; DCM, dilated
cardiomyopathy; BSA, body surface area; SAP, systolic aortic pres-
sure; LVEDDI, left ventricular end-diastolic diameter index; LVESDI,
left ventricular end-systolic diameter index; EF, ejection fraction;
MPAP, mean pulmonary arterial pressure; CI, cardiac index. Data
are expressed as means  SD or number of patients. * = Po 0.05 vs.
NF subjects, at the multiple comparison test (Tukey).
Fig. 1 Representative human myocytes enzymatically isolated from
two left ventricles of non-failing (A, tentative donor) and failing
(B, dilated cardiomyopathy) human hearts.
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supplemented with 100 U mL1 penicillin G and 0.1 mg mL1
streptomycin and incubated under an atmosphere of 95% air
plus 5% CO2 at 37 1C. After 30 min, the medium was changed
with DMEM containing normal (NG, 5 mM) or high glucose
(HG, 25 mM) concentrations corresponding to plasma levels
of 100 and 450 mg dL1, respectively (2 h pre-incubation
under an atmosphere of 95% air plus 5% CO2 at 37 1C).
8
Myocytes were then stimulated with Ang II (100 nM)8,16 or
interleukin-6 (IL-6, 10 ng mL1). To investigate the relative role of
the two angiotensin receptor subtypes, myocytes were preincubated
for 30 min with selective Ang II type 1 (AT1) or Ang II type 2
(AT2) receptor antagonists (Valsartan, 1 mM or PD123319, 1 mM,
respectively). In addition, we performed experiments in the
presence of a flavoprotein inhibitor (diphenyleneiodonium
[DPI], 100 mM), and an inhibitor of mitochondrial reactive
oxygen species (ROS) production (rotenone, 5 mM). To
investigate the effects of ERK1/2, JAK2, and p38MAPK
inhibition, myocytes were preincubated for 60 min with
ERK1/2 inhibitor (PD98059, 30 mM), JAK2 inhibitor
(AG490, 10 mM), or p38MAPK inhibitor (SB203580, 10 mM).
At baseline and after 15, 30 and 60 min, the conditioned
media and myocytes were separated by centrifugation and
immediately frozen at –80 1C.
Western blot analysis
Myocytes suspension was homogenized in RIPA buffer con-
taining protease inhibitor cocktail (Sigma-Aldrich, Milan,
Italy) and phosphatase inhibitor cocktail (Sigma-Aldrich).8
Solubilized myocytes proteins (25 mg proteins) were separated
with 8% SDS-PAGE and transferred to a nitrocellulose
membrane (Hybond-ECL, Amersham Biosciences, Piscataway,
New Jersey, USA). The membrane was blocked with 5% fat-free
milk followed by incubation with 1 : 1000 dilution of polyclonal
rabbit anti-JAK2 (Santa Cruz Biotechnology, Inc., CA, USA),
polyclonal rabbit anti-phospho-JAK2 (Tyr1007/1008) (Upstate
Biotechnology, Lake Placid, NY, USA), polyclonal rabbit
anti-STAT2 (Santa Cruz Biotechnology), polyclonal rabbit
anti-phospho-STAT2 (Tyr690) (Cell Signaling Technology,
Danvers, MA, USA), polyclonal rabbit anti-STAT3, poly-
clonal rabbit anti-phospho-STAT3 (Tyr705) (Cell Signaling
Technology), polyclonal rabbit anti-STAT5, or polyclonal
rabbit anti-phospho-STAT5 IgG (Tyr694) (Cell Signaling
Technology).
After washing, the membrane was blocked with the corre-
sponding secondary HRP-conjugated IgG and the specific
bound antibody was visualized using a chemioluminescent
detection system (ECL detection reagents, GE Healthcare,
formerly Amersham Biosciences, Milan, Italy). The amount
of each band was quantified using a densitometer software
(Quantity One, Bio-Rad Laboratories, Milan, Italy). The
membranes previously incubated with primary antibodies for
phosphorylated proteins were incubated in stripping buffer
and then reprobed with the corresponding antibodies against the
native proteins. The intensity of the phospho-immunostained
bands were normalized with the total protein intensities
measured by non-phospho-immunostained bands from the
same blot in order to normalize to the non-phosphorylated
protein. For each protein results are then expressed as the
phosphorylated to total ratio.
Gene expression (reverse transcription-PCR)
The total amount of RNA was extracted with a NucleoSpin
RNA II Kit (Macherey-Nagel, Du¨ren, Germany) and then
reverse transcribed using a TaqMAN Reverse Transcription
Table 2 Sequences (S, sense; AS, antisense), cDNA sizes and thermal profiles of primers used for investigation of Fas-L, Bcl-xL, IRF-1 and
GAPDH gene expression in human and rat cardiomyocytes
Primers Sequence 50-30 Size/bp
Hot start/
1C s1
Thermal profiles/1C s1
Final extension/
1C min1
No. of
cyclesDenaturation Annealing Extension
Human
Fas-L
S AGGCAAGTCCAACTCAAGGTCC 238 95/300 95/30 58/30 72/60 72/7 35
AS CATCTTCCCCTCCATCATCACC
Bcl-xL
S GGAGCTGGTGGTTGACTTTCT 379 94/120 94/30 52/60 72/120 72/7 40
AS CCGGAAGAGTTCATTCACTAC
IRF-1
S CTTAAGAACCAGGCAACCTCTGCCTTC 406 95/60 95/60 55/60 72/60 72/7 25
AS GATATCTGGCAGGGAGTTCATG
GAPDH
S CATGGCACCGTCAAGG 245 95/300 95/30 55/30 72/30 72/7 25
AS CACCATGGGGGCATCAGC
Rat
Fas-L
S GGAATGGGAAGACACATATGGAACTGC 238 94/180 94/300 60/60 72/60 72/7 35
AS CATATCTGGCCAGTAGTGCAGTAATTC
Bcl-xL
S AGGATACAGCTGGAGTCAG 417 95/180 95/50 61/50 72/50 72/7 31
AS TCTCCTTGTCTACGCTTTCC
IRF-1
S CTTCAGAGCTTAGGAGGCAGGGTCT 450 94/180 94/30 62/60 72/120 72/7 28
AS AGCAGGCACAGGGCAAGGCACTATA
GAPDH
S GGTCGGTGTGAACGGATTTG 350 94/300 94/60 60/60 72/60 72/10 30
AS GTGAGCCCCAGCCTTCTCCAT
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Reagents kit (Applied Biosystem, Monza, Italy) according to
the manufacturer’s protocol. cDNA was then amplified using
specific primer sequences, thermal profiles and number of
cycles for each investigated gene (Fas-L, Bcl-xL, IRF-1, and
GAPDH) (Table 2). Expression of these mRNAs was examined
using ethidium bromide-stained agarose gel electrophoresis.
The band intensity of the PCR products was quantified by
using the public domain NIH Image program (ImageJ).
Statistical analysis
Statistical analysis was performed using SPSS Statistical
Software 14.0 (SPSS Inc., Chicago, IL). Data are expressed
as mean  SD. Comparisons between groups were performed
using one-way analysis of variance, followed by the Tukey
multiple-range comparison test, as appropriate. In addition,
the response to different stimulations, expressed as a ratio
to one point (such as the signal measured in the presence of
buffer only), were compared with a non-parametric test (Kruskal–
Wallis). A value of P o 0.05 was considered statistically
significant.
Results and discussion
Ang II-induced STAT3 phosphorylation and gene expression in
non-failing myocytes
As expected, Ang II-induced JAK2 activation (187 40% and
213  43% vs. buffer at 30 and 60 min, respectively; Po 0.05
for both at the Tukey post hoc test) was closely associated with
STAT3 Tyr705 phosphorylation only in the presence of HG
concentration (186  45% and 206  47% vs. buffer at 30 and
60 min, respectively; Po 0.05 for both) (Fig. 2A). Differently
from Ang II, IL-6-induced STAT3 phosphorylation occurred
independently by glucose concentrations (positive control,
Fig. 2B). STAT3 phosphorylation was selectively inhibited
by AT1 receptor antagonist, JAK2 inhibitor, and by inhibitors
of ROS generation (DPI; Rotenone), being not affected by
ERK1/2 inhibition (Fig. 2B). No STAT2 and STAT5 activa-
tion was observed in non-failing human cardiomyocytes under
any experimental conditions (Fig. 2B).
Experiments performed in rat myocytes showed that Ang II
induced the expression of Fas-L, independently of glucose
Fig. 2 In non-failing human cardiomyocytes Ang II-induced STAT3 tyrosine phosphorylation in the presence of high glucose concentrations is
mediated by AT1 receptor subtypes via JAK2 activation and ROS generation. (A) Upper panels: representative Western blots performed by using
anti-phospho-JAK2 (pTyr1007/1008 JAK2), anti-JAK2 (JAK2), anti-phospho-STAT3 (pTyr705 STAT3), and anti-STAT3 (STAT3) antibodies
on lysates of myocytes at baseline and after 15, 30, and 60 min of stimulation with Ang II (100 nM) in the presence of normal (NG, 5 mM), or high
glucose (HG, 25 mM) concentrations (2 h of pre-incubation with glucose). Lower graphs: time course of changes of phosphorylated-to-total JAK2
(pTyr1007/1008 JAK2/JAK2, left) and STAT3 (pTyr705 STAT3/STAT3, right) ratios induced by buffer or by Ang II in the presence of NG or
HG. Data, expressed as per cent increase relative to the buffer, are means  SD of six separate experiments (* = P o 0.05 vs. buffer at Tukey
t test). (B) Upper panels: representative Western blots performed by using anti-phospho-STAT3 (pTyr705 STAT3), anti-STAT3 (STAT3), anti-
phospho-STAT2 (pTyr690 STAT2), anti-STAT2 (STAT2), anti-phospho-STAT5 (pTyr694 STAT5), anti-STAT5 (STAT5) antibodies on lysates
of myocytes preincubated with NG or HG buffer. Effects of inhibition of AT1 (Val,Valsartan, 1 mM) or AT2 receptor subtypes (PD12, PD123319,
1 mM), ERK1/2 (PD98, PD98059, 30 mM), JAK2 (AG, AG490, 10 mM) or ROS generation (DPI, 100 mM; ROT, Rotenone, 5 mM) added 30 or 60 min
before Ang II stimulation in HG buffer. Effects of interleukin-6 (IL-6, 10 ng mL1; 30 min) in the presence of NG or HG buffer. Lower graphs:
Phosphorylated-to-total STAT3 ratio (pTyr705 STAT3/STAT3) quantitated from all experiments. Data, expressed as per cent increase relative to
the buffer, are means  SD of six separate experiments (* = P o 0.05 vs. buffer at Kruskal–Wallis test).
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concentration (0.86  0.39-fold and 0.83  0.35-fold vs. buffer
at 30 and 60 min, respectively; Po 0.05 for both at the Tukey
post hoc test), and the expression of Bcl-xL only in the
presence of HG concentration (1.05  0.39-fold and 0.90 
0.36-fold vs. buffer at 30 and 60 min, respectively; Po 0.05 for
both) (Fig. 3A). No IRF-1 response was detectable under any
experimental conditions (Fig. 3B). Fas-L gene response to
Ang II was abolished by p38MAPK inhibition, whereas ERK1/2
or JAK2 inhibition had no effects (Fig. 3B). Conversely, Bcl-xL
gene overexpression was almost completely inhibited by both
JAK2 and ERK1/2 antagonism, with no effect being played by
p38MAPK inhibition (Fig. 3B).
Ang II-induced STATs phosphorylation and gene expression in
human heart failure
In failing myocytes, Ang II-induced JAK2 activation was
followed by STAT2 Tyr690 phosphorylation, both in ICM
(237  38% and 248  28% vs. buffer at 30 and 60 min,
respectively; Po 0.05 for both at the Tukey post hoc test), and
DCM cardiomyocytes (230  51% and 228  13% vs. buffer
at 30 and 60 min, respectively; P o 0.05 for both) (Fig. 4A).
Similar findings were shown for Ang II-induced STAT5
Tyr694 phosphorylation, both in ICM (222  31% and
260  25% vs. buffer at 30 and 60 min, respectively; P o 0.05
for both) and DCM cardiomyocytes (222  36% and
254  40% vs. buffer at 30 and 60 min, respectively; P o 0.05
for both) (Fig. 4A). No STAT3 activation was observed in
failing human cardiomyocytes under any experimental condi-
tions (Fig. 4A and B). Differently from what was observed in
non-failing myocytes, Ang II-induced JAK2 tyrosine phos-
phorylation in failing human myocytes was independent of
glucose concentration (Fig. 4B). Likewise, Ang II-induced
STAT2 and STAT5 phosphorylation occurred independently
of glucose concentration (Fig. 4B). The preincubation of failing
Fig. 3 In non-failing rat cardiomyocytes Ang II-induced Fas-L mRNA overexpression occurs independently of ERK1/2 and JAK2 activation,
being inhibited by p38MAPK antagonism. Conversely, Bcl-xL gene overexpression is inhibited by both ERK1/2 and JAK2 antagonism. No
response of IRF-1 gene was observed. (A) Upper panels: Representative RT-PCR experiments of Fas-L, Bcl-xL, and GAPDH mRNA expression
in rat myocytes at baseline and after 15, 30, and 60 min of stimulation with buffer or Ang II (100 nM) in the presence of normal (NG, 5 mM), or
high glucose (HG, 25 mM) concentrations (2 h of pre-incubation with glucose). Lower graphs: time course of genes (Fas-L and Bcl-xL)/GAPDH
mRNA ratio expressed as fold increase relative to the buffer, set at 1.0. Data are means  SD of six separate experiments (* = Po 0.05 vs. buffer
at the Tukey t test). (B) Upper panels: representative RT-PCR experiments of Fas-L, Bcl-xL, IRF-1, and GAPDH mRNA expression 30 min after
stimulation with buffer or Ang II in the presence of NG or HG buffer. Effects of inhibition of ERK1/2 (PD, PD98059, 30 mM), JAK2 (AG, AG490,
10 mM), and p38MAPK (SB, SB203580, 10 mM) added 60 min before Ang II stimulation in HG buffer. Lower graphs: fold increase of Fas-L,
Bcl-xL, and IRF-1 mRNA expression (gene/GAPDH ratio) induced by Ang II (30 min) relative to the buffer, set at 1.0. Data are means  SD of
six separate experiments (* = P o 0.05 vs. buffer at the Kruskal–Wallis test).
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myocytes with JAK2 antagonism prevented Ang II-induced
JAK2, STAT2 and STAT5 tyrosine phosphorylation
(Fig. 4B). Ang II-induced JAK2, STAT2 and STAT5 tyrosine
phosphorylation were also abolished by ROS inhibition, both
in ICM and DCM failing cardiomyocytes (Fig. 4B). In human
failing myocytes (DCM) Ang II induced Fas-L gene expres-
sion independently of glucose concentration (1.15  0.27-fold
and 1.28  0.36-fold vs. buffer at 30 and 60 min, respectively;
P o 0.05 for both) (Fig. 5A). Ang II-induced Fas-L response
was abolished by p38MAPK inhibition, being unaffected by
JAK2, or ERK1/2 antagonism (Fig. 5B). Ang II stimulation
failed to enhance Bcl-xL and IRF-1 genes expression in human
failing myocytes (Fig. 5A and B).
Conclusion
Present findings reveal that (1) in non-failing cardiomyocytes
Ang II induced JAK2 activation is followed by STAT3
activation and Bcl-xL gene overexpression, (2) the gene response
being mediated by a cross-link between ERK1/2 and JAK2,
whereas (3) in failing human cardiomyocytes Ang II-induced
STAT3 and Bcl-xL gene overexpression are abolished, being
replaced by STAT2 and STAT5 activation. Ang II-induced
Fas-L gene overexpression seems to be mediated by a JAK2/
STAT independent pathway (p38MAPK).
In cardiac fibroblasts, Ang II-stimulated generation of ROS17
directly allows the activation of a ROS-sensitive tyrosine kinase,
JAK2.18 Differently from fibroblasts,19 non-failing adult cardio-
myocytes require the presence of high glucose levels, causing a
marked increase of NADPH oxidase activity,20 to allow Ang II-
mediated JAK2 activation.8 A similar effect was also observed
in mesangial cells.21
In non-failing myocytes STAT3 activation was inhibited by
JAK2 antagonism. Although STAT3 activation is usually
associated with pro-hypertrophic and cardioprotective response,22
information linking STAT3 to specific target genes in adult
cardiomyocytes is limited. Data obtained from a mouse
embryonic fibroblast cell line (NIH3T3 cells) indicated Fas-L
Fig. 4 Ang II-stimulation in human failing cardiomyocytes (obtained from patients with ischemic, ICM n = 8, or dilated, DCM n = 8,
cardiomyopathy) is followed by STAT2 and STAT5 tyrosine phosphorylation whereas the STAT3 response observed in non-failing (NF)
cardiomyocytes is abolished. (A) Left panels: representative Western blots performed by using anti-phospho-JAK2 (pTyr1007/1008 JAK2), anti-
JAK2 (JAK2), anti-phospho-STAT3 (pTyr705 STAT3), anti-STAT3 (STAT3), anti-phospho-STAT2 (pTyr690 STAT2), anti-STAT2 (STAT2),
anti-phospho-STAT5 (pTyr694 STAT5), anti-STAT5 (STAT5) antibodies on lysates of human NF and failing (ICM, DCM) myocytes stimulated
with Ang II (100 nM) in the presence of high glucose (HG, 25 mM) concentrations (2 h of pre-incubation with glucose). Right graphs: time course
of changes of phosphorylated-to-total JAK2 (pTyr1007/1008 JAK2/JAK2), STAT3 (pTyr705 STAT3/STAT3), STAT2 (pTyr690 STAT2/
STAT2), STAT5 (pTyr694 STAT5/STAT5) ratios induced by Ang II in the presence of HG. Data are means  SD of three separate experiments
for NF cells and of eight separate experiments for both ICM and DCM cells (* = P o 0.05 vs. buffer at the Tukey t test). (B) Left panels:
representative Western blots of the effects of JAK2 (AG, AG490, 10 mM) and ROS antagonism (DPI, 100 mM) on JAK2, STAT3, STAT2, and
STAT5 phosphorylation in NF, ICM and DCM ventricular myocytes stimulated with Ang II (30 min) in the presence of normal glucose
(NG, 5 mM) concentrations. Negative and positive controls are represented by stimulation with buffer and interleukin-6 (IL-6, 10 ng mL1),
respectively. Means  SD are reported in the right graphs and are the results of three separate experiments for NF cells and of eight separate
experiments for both ICM and DCM cells (* = P o 0.05 vs. buffer at the Kruskal–Wallis test).
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as a target gene for tyrosine-phosphorylated STAT3.14 Direct
identification of STATs target genes is however limited by the
possible interaction with other intracellular pathways. Present
data indeed indicate that at least in human ventricular myo-
cytes, a major role in Fas-L gene expression is played by the
p38MAPK pathway, rather than by JAK2/STAT3, stressing
the importance of considering the cell type in the heart and the
limitation to extend results to different tissue or cell lines. In
neonatal cardiomyocytes, Fas-L overexpression was indeed
reported to be activated by a JAK2 independent pathway
mediated by p38MAPK serine phosphorylation of STAT1.23,24
Our results do not exclude the possible participation of STAT1.
Differently from Fas-L, Ang II-stimulated Bcl-xL gene expres-
sion was blunted by JAK2 inhibition. Bcl-xL gene overexpres-
sion was also inhibited by ERK1/2 antagonism. ERK1/2
antagonism however did not affect JAK2 or STAT3 tyrosine
phosphorylation, so that ERK1/2 and JAK2 seem to cooperate
to induce Bcl-xL gene expression. These observations might be
in line with previous data obtained in human fibroblast cell
lines indicating that full transcriptional activity of STAT3
requires both tyrosine and serine phosphorylation,7 STAT3
being a better substrate for ERK1/2 than for p38MAPK.25
Therefore, in human cardiomyocytes, as well as in fibroblasts,
Bcl-xL seems to be linked to STAT3, the transcriptional
activity of STAT3 being enforced by ERK1/2. The observed
STAT3 activation induced by Ang II in the presence of high
glucose may have relevant implications. Glucose concentra-
tions used in in vitro study can be reached in vivo so that the
possible participation of this mechanism in diabetic cardio-
myopathy can be hypothesized.
The downstream STATs response of failing myocytes is
peculiar because Ang II-induced JAK2 activation, which
occurs independently of glucose concentration, is not followed
by the STAT3 phosphorylation observed in non-failing cells.
The impaired STAT3 response is consistent with the reduced
number of STAT3-positive cardiomyocytes observed in left
Fig. 5 In failing human cardiomyocytes Ang II-induced Fas-L mRNA overexpression occurs independently of ERK1/2 and JAK2 activation,
being inhibited by p38MAPK antagonism. No responses of Bcl-xL or IRF-1 genes were observed. (A) Upper panels: representative RT-PCR
experiments of Fas-L, Bcl-xL, and GAPDH mRNA expression in human failing myocytes (DCM) at baseline and after 15, 30, and 60 min of
stimulation with buffer or Ang II (100 nM) in the presence of normal (NG, 5 mM), or high glucose (HG, 25 mM) concentrations (2 h of pre-
incubation with glucose). Lower graphs: time course of genes (Fas-L and Bcl-xL)/GAPDH mRNA ratio expressed as fold increase relative to the
buffer, set at 1.0. Data are means  SD of four separate experiments (* = Po 0.05 vs. buffer at the Tukey t test). (B) Upper panels: representative
RT-PCR experiments of Fas-L, Bcl-xL, IRF-1, and GAPDH mRNA expression in human failing myocytes (DCM) 30 min after stimulation with
buffer or Ang II in the presence of NG or HG buffer. Effects of inhibition of ERK1/2 (PD, PD98059, 30 mM), JAK2 (AG, AG490, 10 mM), or
p38MAPK (SB, SB203580, 10 mM) added 60 min before Ang II stimulation in HG buffer. Lower graphs: fold increase of Fas-L, Bcl-xL, and IRF-1
mRNA expression (gene/GAPDH ratio) induced by Ang II (30 min) relative to the buffer, set at 1.0. Data are means  SD of four separate
experiments (* = P o 0.05 vs. buffer at the Kruskal–Wallis test).
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ventricle preparations of human failing hearts.2 The combined
alterations of STAT3 and ERK1/2 activation observed in
failing human ventricular myocytes might be responsible for
the altered Bcl-xL response.
The functional meaning of STAT2 and STAT5 Ang II-
mediated activation in human failing cardiomyocytes needs
further investigations, although an involvement of up-regulation
of pro-inflammatory pathways can be hypothesized. STAT2 is
the member of the family related to the interferon (IFN)-like
responses,26 and it may be surmised that STAT2 activation
contributes to the myocardial inflammation present in the
advanced heart failure. The activation of STAT5 by Ang II
might promote an autocrine loop for the maintenance of
cardiac Ang II generation since angiotensinogen gene promoter
in myocytes is a target of activated STAT5.27
Limitations of our study need to be considered. Notwith-
standing the value of obtaining present data in isolated
ventricular myocytes rather than in homogenated hearts, the
number of subjects investigated was low, due to the particularly
limited availability of non-failing human cardiomyocytes. We
can also consider the possibility that Ang II antagonists and
beta-blockers assumed by patients might have played a role in
the observed altered signaling response in human left ventri-
cular cardiomyocytes. However, previous studies reported that
the assumption of prescribed drugs had no residual effect on
Ang II-induced gene expression,16 JAK2 phosphorylation,8 or
ERK1/2 activation,9 after cardiomyocytes isolation. In a very
recent paper Vergara et al.28 demonstrated that the signalling
response triggered by ERK1/2 is down-regulated in ovarian
cancer cells after treatment with a phytochemical involved in
many cellular signalling pathways indicating a possible evidence
of the potential protective action of antioxidant molecules.
Experimental studies also provided insights regarding the role
played by ROS overproduction in the cardiac dysfunction, so
further studies will be needed to fully clarify the role of ROS
generation in failing human cardiomyocytes. From a clinical
point of view, conflicting results of randomized placebo-
controlled trials investigating the effects of antioxidants therapies
challenge researchers to evaluate the ideal study patients to study,
and the appropriate trial duration.29,30
Finally, the present study can be considered mainly obser-
vational because the mechanisms responsible for the altered
STATs response in human cardiomyocytes in failing hearts
still remain to be clarified.
To conclude, even with limitations, our results may have
relevant clinical implications because the onset of an impaired
STAT3 response may further facilitate the progression to failure.
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